Evidence map›Paper›PMID 39702316›Full record

ArticleAlzheimer's research & therapy2024

Structural and functional alterations of neurons derived from sporadic Alzheimer's disease hiPSCs are associated with downregulation of the LIMK1-cofilin axis.

Raimondo Sollazzo, Domenica Donatella Li Puma, Giuseppe Aceto, Fabiola Paciello, Claudia Colussi, Maria Gabriella Vita, Guido Maria Giuffrè, Francesco Pastore, Alessia Casamassa, Jessica Rosati and 6 more

Abstract read
In one paragraph

Article in Alzheimer's research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Neuronal Actin Remodeling and Its Role in Higher Nervous Activity.International journal of molecular sciences · 2025
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Raimondo SollazzoDepartment of Neuroscience, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
Domenica Donatella Li PumaDepartment of Neuroscience, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
Giuseppe AcetoDepartment of Neuroscience, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
Fabiola PacielloDepartment of Neuroscience, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
Claudia ColussiFondazione Policlinico Universitario A. Gemelli IRCCS, 00168, Rome, Italy.
Maria Gabriella VitaFondazione Policlinico Universitario A. Gemelli IRCCS, 00168, Rome, Italy.
Guido Maria GiuffrèFondazione Policlinico Universitario A. Gemelli IRCCS, 00168, Rome, Italy.
Francesco PastoreDepartment of Neuroscience, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
Alessia CasamassaCellular Reprogramming Unit, Fondazione IRCCS Casa, Sollievo Della Sofferenza, 71013 - San Giovanni, Rotondo, Italy.
Jessica RosatiCellular Reprogramming Unit, Fondazione IRCCS Casa, Sollievo Della Sofferenza, 71013 - San Giovanni, Rotondo, Italy.
Agnese NovelliDepartment of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
Sabrina MaiettaDepartment of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
Francesco Danilo TizianoFondazione Policlinico Universitario A. Gemelli IRCCS, 00168, Rome, Italy.
Camillo MarraDepartment of Neuroscience, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
Cristian RipoliDepartment of Neuroscience, Università Cattolica del Sacro Cuore, 00168, Rome, Italy. cristian.ripoli@unicatt.it.
Claudio GrassiDepartment of Neuroscience, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlzheimer's Disease (AD) is a neurodegenerative disorder characterized by the accumulation of pathological proteins and synaptic dysfunction. This study aims to investigate the molecular and functional differences between human induced pluripotent stem cells (hiPSCs) derived from patients with sporadic AD (sAD) and age-matched controls (healthy subjects, HS), focusing on their neuronal differentiation and synaptic properties in order to better understand the cellular and molecular mechanisms underlying AD pathology.

methodsSkin fibroblasts from sAD patients (n = 5) and HS subjects (n = 5) were reprogrammed into hiPSCs using non-integrating Sendai virus vectors. Through karyotyping, we assessed pluripotency markers (OCT4, SOX2, TRA-1-60) and genomic integrity. Neuronal differentiation was evaluated by immunostaining for MAP2 and NEUN. Electrophysiological properties were measured using whole-cell patch-clamp, while protein expression of Aβ, phosphorylated tau, Synapsin-1, Synaptophysin, PSD95, and GluA1 was quantified by western blot. We then focused on PAK1-LIMK1-Cofilin signaling, which plays a key role in regulating synaptic structure and function, both of which are disrupted in neurodegenerative diseases such as AD.

resultssAD and HS hiPSCs displayed similar stemness features and genomic stability. However, they differed in neuronal differentiation and function. sAD-derived neurons (sAD-hNs) displayed increased levels of AD-related proteins, including Aβ and phosphorylated tau. Electrophysiological analyses revealed that while both sAD- and HS-hNs generated action potentials, sAD-hNs exhibited decreased spontaneous synaptic activity. Significant reductions in the expression of synaptic proteins such as Synapsin-1, Synaptophysin, PSD95, and GluA1 were found in sAD-hNs, which are also characterized by reduced neurite length, indicating impaired differentiation. Notably, sAD-hNs demonstrated a marked reduction in LIMK1 phosphorylation, which could be the underlying cause for the changes in cytoskeletal dynamics that we found, leading to the morphological and functional modifications observed in sAD-hNs. To further investigate the involvement of the LIMK1 pathway in the morphological and functional changes observed in sAD neurons, we conducted perturbation experiments using the specific LIMK1 inhibitor, BMS-5. Neurons obtained from healthy subjects treated with the inhibitor showed similar morphological changes to those observed in sAD neurons, confirming that LIMK1 activity is crucial for maintaining normal neuronal structure. Furthermore, administration of the inhibitor to sAD neurons did not exacerbate the morphological alterations, suggesting that LIMK1 activity is already compromised in these cells.

conclusionOur findings demonstrate that although sAD- and HS-hiPSCs are similar in their stemness and genomic stability, sAD-hNs exhibit distinct functional and structural anomalies mirroring AD pathology. These anomalies include synaptic dysfunction, altered cytoskeletal organization, and accumulation of AD-related proteins. Our study underscores the usefulness of hiPSCs in modeling AD and provides insights into the disease's molecular underpinnings, thus highlighting potential therapeutic targets.

Indexed as

Alzheimer DiseaseDown-RegulationInduced Pluripotent Stem CellsLim KinasesNeuronsActin Depolymerizing FactorsAgedCell DifferentiationCells, CulturedFemaleFibroblastsHumansMaleMiddle Agedp21-Activated KinasesSignal TransductionActin Depolymerizing FactorsLIMK1 protein, humanLim Kinasesp21-Activated KinasesPAK1 protein, humanAlzheimer’s diseasehiPSCsHuman neuronsLIMK1NeuritesSynaptic function

Identifiers

PMID39702316
PMCPMC11660640

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.